Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ginkgo Bioworks Holdings (DNABW) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Ginkgo Bioworks Holdings (DNABW) over the last 6 years, with Q3 2025 value amounting to 207.05%.

  • Ginkgo Bioworks Holdings' EBITDA Margin fell 1459400.0% to 207.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 187.04%, marking a year-over-year increase of 1102800.0%. This contributed to the annual value of 242.39% for FY2024, which is 1110600.0% up from last year.
  • Ginkgo Bioworks Holdings' EBITDA Margin amounted to 207.05% in Q3 2025, which was down 1459400.0% from 116.52% recorded in Q2 2025.
  • In the past 5 years, Ginkgo Bioworks Holdings' EBITDA Margin ranged from a high of 34.37% in Q3 2021 and a low of 1134.55% during Q4 2021
  • In the last 5 years, Ginkgo Bioworks Holdings' EBITDA Margin had a median value of 249.97% in 2024 and averaged 354.45%.
  • Over the last 5 years, Ginkgo Bioworks Holdings' EBITDA Margin had its largest YoY gain of 9638200bps in 2022, and its largest YoY loss of -9785300bps in 2022.
  • Over the past 5 years, Ginkgo Bioworks Holdings' EBITDA Margin (Quarter) stood at 1134.55% in 2021, then soared by 85bps to 170.73% in 2022, then plummeted by -249bps to 596.49% in 2023, then skyrocketed by 58bps to 249.97% in 2024, then grew by 17bps to 207.05% in 2025.
  • Its EBITDA Margin was 207.05% in Q3 2025, compared to 116.52% in Q2 2025 and 186.27% in Q1 2025.